Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of SYN008 vs Xolair in chronic spontaneous urticaria
2021-000149-42Phase 3Terminated
- Sponsor
- Xingmeng Biopharmaceutical
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omalizumab biosimilar SYN008 in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Xingmeng Biopharmaceutical. Primary endpoint: Change from baseline to Week 12 in weekly itch-severity score (ISS7). Started Jun 2021; status: terminated.
02
Drugs
omalizumab biosimilar SYN008
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2021-000149-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000149-42.